TGFB1 and neoplasm: As PD-L1 and TGFβ entrain independent but cooperative mechanisms of immune tolerance, autocrine and paracrine TGFβ signaling in the tumor immune microenvironment may also limit the therapeutic efficacy of PD-1/PD-L1 antagonists.